Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cocktail · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325 | EXPERIMENTAL | Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1 Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15 Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30 Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only |
| Name | Type | Description |
|---|---|---|
| Cocktail | DRUG | Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg |
| DCV 3DAA FDC | DRUG | DCV 30 mg + ASV 200 mg + BMS-791325 75 mg |
| BMS-791325 | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examinations, vital sign measurements, 12-lead ECG measurements...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Cocktail is an investigational small molecule combination being studied for Hepatitis C. It combines daclatasvir, asunaprevir, and BMS-791325 in a fixed-dose tablet. The drug is in Phase 1 clinical development and is not approved by the FDA.
Cocktail is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug for the treatment of Hepatitis C.
Cocktail is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed to assess the drug's potential interactions with other medications.
Cocktail has one completed clinical trial, NCT02045966. This Phase 1 study evaluated the drug interactions when the daclatasvir, asunaprevir, and BMS-791325 combination tablet is coadministered with a cocktail of cytochrome P450 probe substrates and transporter probe substrates in healthy subjects.
Yes, Cocktail refers to a fixed-dose combination tablet containing daclatasvir, asunaprevir, and BMS-791325. This three-drug antiviral combination is being studied for Hepatitis C. The clinical trial NCT02045966 specifically evaluates this combination tablet.